Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: Beneficial effect of modest weight loss and exercise on liver biopsy findings

Endocrine Practice

Volumn 11, Issue 5, 2005, Pages 319-324

  Brown, Ann J ^a   Tendler, David A ^b   McMurray, Robert G ^c   Setji, Tracy L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Durham Gastroenterology Consultants   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; INSULIN; TESTOSTERONE;

ADULT; ARTICLE; BIOPSY; BLOOD; CASE REPORT; EXERCISE; FATTY LIVER; FEMALE; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIVER; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; WEIGHT REDUCTION;

ADULT; BIOPSY; EXERCISE; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TESTOSTERONE; TRANSAMINASES; WEIGHT LOSS;

EID: 33644972717     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.5.319     Document Type: Article

References (21)

1. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 1987; 65:499-507.
2. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinol Metab Clin North Am. 1999;28:247-263.
3. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607-613.
4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-3082.
5. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology. 1999;116:1413-1419.
6. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669.
7. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis [erratum in Ann Intern Med. 1997;127(8 Pt 1):658]. Ann Intern Med. 1997;126:137-145.
8. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology. 2002;35:373-379.
9. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372.
10. Chang RJ, Katz SE. Diagnosis of polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999;28:397-408, vii.
11. Marsden PJ, Murdoch AP, Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2001;55:191-199.
12. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-169.
13. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174.
14. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. 1999;28:361-378.
15. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human theca cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83:2001-2005.
16. Nestler JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1989;68:1027-1032.
17. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139-146.
18. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:3299-3306.
19. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000;73:150-156.
20. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998-1003.
21. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-525.